<DOC>
	<DOC>NCT00404820</DOC>
	<brief_summary>The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.</brief_summary>
	<brief_title>Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Low bone mineral density (as indicated by a "tscore" of 2.0 or lower) postmenopausal women Previous use of oral and iv bisphosphonates, parathormone, strontium ranelate, sodium fluoride. Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>biomarker</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>alendronate</keyword>
	<keyword>postmenopausal</keyword>
</DOC>